TRACT Therapeutics
TRACT Therapeutics is dedicated to developing innovative, personalized cellular therapies to improve transplant medicine and autoimmune disease treatment. Their flagship product, TregCel™, utilizes a patient's own regulatory T cells to establish immune tolerance, potentially reducing or eliminating the need for lifelong immunosuppressive drugs. The company aims to enhance long-term organ transplant success and treat autoimmune disorders, with ongoing clinical trials and strategic partnerships to advance their technology.
Industries
Nr. of Employees
small (1-50)
TRACT Therapeutics
400 N. Aberdeen St, Suite 900, Chicago, IL 60642
Products
Autologous regulatory T cell therapeutic (autologous Treg product)
A personalized cell therapy derived from a patient's own regulatory T cells that are isolated, expanded ex vivo, cryopreserved if needed, and administered by IV infusion to promote immune tolerance in organ transplantation and autoimmune disease.
Autologous regulatory T cell therapeutic (autologous Treg product)
A personalized cell therapy derived from a patient's own regulatory T cells that are isolated, expanded ex vivo, cryopreserved if needed, and administered by IV infusion to promote immune tolerance in organ transplantation and autoimmune disease.
Services
Sponsorship and conduct of early-phase clinical studies in organ transplant and autoimmune indications, including safety monitoring and biomarker evaluation.
Transfer of manufacturing processes and platform know-how to external manufacturing facilities to support scale-up and trial advancement.
Development and implementation of streamlined manufacturing workflows for autologous Treg products, including selection, expansion, and final product shipping.
Sponsorship and conduct of early-phase clinical studies in organ transplant and autoimmune indications, including safety monitoring and biomarker evaluation.
Transfer of manufacturing processes and platform know-how to external manufacturing facilities to support scale-up and trial advancement.
Development and implementation of streamlined manufacturing workflows for autologous Treg products, including selection, expansion, and final product shipping.
Expertise Areas
- Regulatory T cell (Treg) adoptive cell therapy development
- Autologous cell therapy manufacturing and scale-up
- Early-phase clinical trial design and execution (cell therapy)
- Translational transplant immunology
Key Technologies
- Treg adoptive cell transfer
- Leukapheresis collection
- Ex vivo cell expansion
- Polyclonal Treg expansion to high-dose formulations
News & Updates
Announcement of successful technology transfer to Taiwan Bio's manufacturing facility.
Announcement of a poster presentation at the American Transplant Congress 2024.
Announcement of a new strategic partnership to advance Phase 2 trial in living donor kidney transplant.
Early clinical success in organ transplantation
Phase 1 clinical trial demonstrated safety and no rejection in kidney transplant patients.
Orphan Drug Designation for TregCel™
Granted for the prevention of graft rejection following solid organ transplantation.
Announcement of successful technology transfer to Taiwan Bio's manufacturing facility.
Announcement of a poster presentation at the American Transplant Congress 2024.
Announcement of a new strategic partnership to advance Phase 2 trial in living donor kidney transplant.
Early clinical success in organ transplantation
Phase 1 clinical trial demonstrated safety and no rejection in kidney transplant patients.
Orphan Drug Designation for TregCel™
Granted for the prevention of graft rejection following solid organ transplantation.